#USA #MedTech #Veeva Systems #Clinical Trials #Pleasanton

Focus on Collaboration and Data Quality in MedTech

Recent insights from the 2025 Veeva MedTech Clinical Benchmark reveal that medtech clinical teams are placing a significant emphasis on enhancing their collaboration with research sites. According to the report by Veeva Systems, nearly 70% of respondents identified the reduction of manual processes as a key priority. This focus stems from a collective understanding that optimizing these operations can substantially boost the quality of clinical trials while promoting transparency and oversight.

Streamlining Clinical Operations

A marked 68% of medtech professionals emphasize that minimizing manual handling of data and procedural tasks is essential for more streamlined interactions with research sites. This is critical as challenges like on-time data entry and document exchange have emerged as major obstacles in site management. Alarmingly, only a small portion of medtech companies use effective site collaboration tools, with only 14% of firms exceeding $1 billion in revenue having implemented such systems.

The Need for Improvement

The benchmark report illustrates a noticeable gap within the industry regarding efficiency in trials. Despite recognizing the hurdles of manual processes, which account for a risk increase of 32%, a large number of companies are still not prioritizing necessary technology investments to mitigate these issues. Moreover, compliance with global regulations and readiness for inspections—cited by 18% of respondents—are further complicating efforts to modernize clinical practices.

Data Management Strategies

To counter these challenges, 58% of those surveyed intend to prioritize data collection and cleansing initiatives in the upcoming year. By refining these processes, medtech companies aim to direct their resources toward high-value activities that contribute directly to trial success instead of wasting time on data reconciliation.

Embracing New Technologies

Interestingly, the industry is showing signs of progress with plans to invest in artificial intelligence (AI) and machine learning (ML), with 72% of organizations looking to upgrade their infrastructure to support these technologies. Harmonizing current systems and standardizing data for AI applications appear to be essential steps that many companies recognize as necessary for future development.

Kevin Liang, vice president of clinical strategy at Veeva, remarked, "The medtech industry is driving initiatives to advance clinical processes, site collaboration, and data quality amidst economic pressures and new regulations." This statement underlines the commitment within the sector to not only improve operational efficiency but also accelerate the introduction of innovative technologies to patients.

Conclusion

The 2025 Veeva MedTech Clinical Benchmark reflects a pivotal moment for the medtech industry, showcasing a clear transition toward enhanced collaboration, improved data quality, and standardized practices. As teams work diligently to overcome existing challenges, the focus on driving efficiency will undoubtedly impact the speed and effectiveness of future clinical trials. For more insights, the full report provides a comprehensive overview of the current landscape in medtech clinical trials and outlines specific strategies for modernizing operations.

• ---

For more information about Veeva MedTech and their offerings, visit their website.